Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.56 |
| ▸ | TTPA | P49638 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 10/20 | 0.44 |
| ▸ | ACHE | P22303 | 10/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16247656 | 0.91 | PSEN1 (0.52) | PSEN1TTPAPTPN1GSTO1BCHE | |
| SCHEMBL2059270 | 0.87 | TTPA (0.67) | PSEN1TTPABCHEACHE | |
| SCHEMBL16207521 | 0.85 | PSEN1 (0.74) | PSEN1TTPAPTPN1GSTO1PTGS1 | |
| SCHEMBL16207469 | 0.85 | PSEN1 (0.74) | PSEN1TTPAPTPN1GSTO1PTGS1 | |
| SCHEMBL16207505 | 0.85 | PSEN1 (0.74) | PSEN1TTPAPTPN1GSTO1PTGS1 | |
| SCHEMBL16207554 | 0.85 | PSEN1 (0.74) | PSEN1TTPAPTPN1GSTO1PTGS1 | |
| SCHEMBL14950742 | 0.83 | TTPA (0.55) | PSEN1TTPAPTPN1GSTO1BCHE | |
| SCHEMBL16247647 | 0.83 | PSEN1 (0.59) | PSEN1TTPAPTPN1GSTO1PTGS1 | |
| SCHEMBL16247640 | 0.83 | PSEN1 (0.59) | PSEN1TTPAPTPN1GSTO1PTGS1 | |
| SCHEMBL16247645 | 0.83 | PSEN1 (0.59) | PSEN1TTPAPTPN1GSTO1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206192-B2 | Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof | Jiangsu Chiatei Tianqing Pharmaceutical Co., LTd (CN) | 2015-12-08 | — | — | US | disclosed |
| US-20140343088-A1 | TROLOX DERIVATIVE-MODIFIED FAT-SOLUBLE ANTI-CANCER PHARMACEUTICAL COMPOUNDS, PREPARATIONS, PREPARING METHODS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343088-A1 | TROLOX DERIVATIVE-MODIFIED FAT-SOLUBLE ANTI-CANCER PHARMACEUTICAL COMPOUNDS, PREPARATIONS, PREPARING METHODS AND USE THEREOF | TTPA, PLIN1, PLIN5 | PSEN1 2379/4885TTPA 1/4885PTPN1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.